receives funding from OpenTargets and Nerviano Medical Sciences; is a scientific advisor for Drug ReKindle; and is a consultant for CoSyne Therapeutics.
has received funding from Open Targets, AstraZeneca, GlaxoSmithKline and Astex Pharmaceuticals; holds equity and is a paid consultant for Mosaic Therapeutics; and is a paid advisor for Bristol Myers Squibb.
is a cofounder and scientific advisor of Myllia Biotechnology and Neurolentech.
has received funding from Open Targets and AstraZeneca.
D.W. is an employee of Cancer Research Horizons.
Competing interests
F.I. receives funding from OpenTargets and Nerviano Medical Sciences; is a scientific advisor for Drug ReKindle; and is a consultant for CoSyne Therapeutics. M.J.G. has received funding from Open Targets, AstraZeneca, GlaxoSmithKline and Astex Pharmaceuticals; holds equity and is a paid consultant for Mosaic Therapeutics; and is a paid advisor for Bristol Myers Squibb. C.B. is a cofounder and scientific advisor of Myllia Biotechnology and Neurolentech. M.K. is a co-founder, shareholder and chief officer of Vivlion. C.J.L. receives and/or has received research funding from AstraZeneca, Merck KGaA, Artios, Neophore and FoRx; received consultancy, scientific advisory board membership or honoraria payments from FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, ForEx and Ariceum; has stock in Tango, Ovibio, Hysplex, Tesselate, Ariceum; is a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the Institute of Cancer Research ‘Rewards to Inventors’ scheme; and reports benefits from this scheme associated with patents for PARP inhibitors paid into their personal account and research accounts at the Institute of Cancer Research. E.P. has received funding from Open Targets and AstraZeneca. J.L.S.-B. is a co-founder and shareholder of LAMPseq diagnostics and ions.bio. L.T. has received funds from Menarini, Merck, Merus, Pfizer, Servier and Symphogen. D.W. is an employee of Cancer Research Horizons. L.W. has received funds from Bristol Myers Squibb. The other authors declare no competing interests.
